Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

By Ursula Schmidt-Erfurth, P. Kaiser, J. Korobelnik, David M. Brown, V. Chong, Q. Nguyen, A. Ho, Y. Ogura, Christian Simader, G. Jaffe and 12 more. Ophthalmology (Rochester, Minn.), 2014

809 citations recorded by the source corpus.

Subfields: Epidemiology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/0b66e227c893eff68fca81d63b1a484ea3096fec

Citations in the corpus

• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial (2016, neutral): “of participants (%) Nonfatal myocardial infarction 7 (3) 3 (1) 6 (3) Nonfatal stroke 2 (<1) 6 (3) 11 (5) Vascular death (from any potential vascular or unknown cause) 3 (1) 8 (4) 9 (4) Any Antiplatelet Trialists’ Collaboration Event 12 (5) 17 (8) 26 (12) 0.”